2024-512196-12-00Not yet recruitingPhase 1
A randomized, placebo-controlled, double-blind, single-ascending-dose, Phase 1a/b study to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of intravenous NTR-641 in healthy adults and patients with acute ischemic stroke
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- First submitted
- 5 Aug 2024
- Start date
- 14 Oct 2024
- Lead sponsor
- Neutrolis Inc.
- Diseases
- Stroke
- EU CT number
- 2024-512196-12-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 72
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Vienna | Vienna | Austria | Not yet recruiting |
| Krankenhaus Der Barmherzigen Brueder Wien | Vienna | Austria | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.